Sibutramine, formerly sold under the brand name Meridia among others, is an appetite suppressant that has been discontinued in many countries due to safety concerns. It works as a serotonin–norepinephrine reuptake inhibitor (SNRI), similar to certain antidepressants, by enhancing the levels of serotonin and norepinephrine in the brain. This action promotes a feeling of fullness, thereby reducing food intake and assisting in weight management.
Parent: Sibutramine
Parent: Sibutramine
Parent: Sibutramine
Parent: Sibutramine
Impurities in Sibutramine can arise due to synthesis processes, degradation, or storage conditions. Regulatory authorities like the FDA, ICH, and EMA enforce strict impurity limits to ensure the drug’s safety and efficacy.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Sibutramine works by inhibiting the reuptake of serotonin and norepinephrine in the brain, which helps increase feelings of fullness and reduce appetite. This mechanism aids in weight loss for obese patients.
Sibutramine has been linked to an increased risk of cardiovascular events, such as heart attacks and strokes, especially in patients with pre-existing heart conditions. Due to these risks, it has been discontinued in many countries.
No, sibutramine has been withdrawn from the market in most countries due to safety concerns, particularly its potential to cause serious cardiovascular side effects.
There is limited evidence directly linking sibutramine to infertility. However, its impact on hormonal balance and cardiovascular health may indirectly affect reproductive function. Consulting a healthcare provider for more information is recommended.
